Expression of Concern
This article is currently under investigation. We strongly recommend that this article is not cited until the investigation is completed.
This article is currently under investigation. We strongly recommend that this article is not cited until the investigation is completed.
Research Paper Volume 12, Issue 11 pp 11025—11041
LncRNA ADAMTS9-AS2 inhibits gastric cancer (GC) development and sensitizes chemoresistant GC cells to cisplatin by regulating miR-223-3p/NLRP3 axis
Figure 2. LncRNA ADAMTS9-AS2 acted as a RNA sponge to regulate miR-223-3p in GC cells. (A) The targeting sites of LncRNA ADAMTS9-AS2 and miR-223-3p were predicted by using the online starBase software (http://hopper.si.edu/wiki/mmti/Starbase). Dual-luciferase reporter gene system was used to verify the binding sites in (B) SGC7901 cells and (C) BGC-823 cells, respectively. (D) RIP was performed to measure the binding abilities of LncRNA ADAMTS9-AS2 and miR-223-3p. Real-Time qPCR was used to examine the expression levels of (E) LncRNA ADAMTS9-AS2 and (F) miR-223-3p in GC cells. Each experiment repeated at least 3 times. “NS” represented “no statistical significance”, *P < 0.05, **P < 0.01.